Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by Arbeitsgruppe Lebermetastasen und Tumoren.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Arbeitsgruppe Lebermetastasen und Tumoren
ClinicalTrials.gov Identifier:
NCT00156975
First received: September 9, 2005
Last updated: December 24, 2009
Last verified: April 2007
  Purpose

Primary endpoint of the study is to prove the superiority of an adjuvant therapy with oxaliplatin/ capecitabine until the first occurrence of appearance of a tumour. Occurrences in the meaning of this study are the appearance of a relapse of the tumour, of metastases, of a second tumour or death of any reason.


Condition Intervention Phase
Colorectal Neoplasms
Liver Metastases
Drug: Capecitabine
Drug: Oxaliplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Adjuvant Chemotherapy With Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases- Randomized Phase III Study

Resource links provided by NLM:


Further study details as provided by Arbeitsgruppe Lebermetastasen und Tumoren:

Primary Outcome Measures:
  • Primary outcomes:
  • Disease free survival

Secondary Outcome Measures:
  • Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity

Estimated Enrollment: 384
Study Start Date: November 2004
Detailed Description:

Prospective, randomized, multi-centre, open phase III study with two parallel groups of patients according to the eligibility criteria. The times in both hierarchical classified endpoints will be measured as times from randomization.

Patients with macroscopic complete resection of colorectal liver metastases will be randomized in:

Arm A: post-operative adjuvant therapy with Capecitabine/ Oxaliplatin over 6 months and follow-up

or

Arm B: follow-up

Randomization: stratification after Scores of Fong et al:

  • number of metastases (1 vs. >=1)
  • maximal diameter of the metastasis (<= 5cm vs. > 5cm)
  • disease free interval (>= 12 months vs. > 12 months)
  • CEA (<= 200ng/l vs. >200 ng/l) in the strata 0-1, 2 and >= 3,
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients after R0-resection of colorectal liver metastases
  • age: >= 18 years
  • Karnofsky-Index >= 70%
  • neutrophiles >1,5 x10e9/l, thrombocytes 100 x10e9/l
  • adequate contraception for male and female patients
  • oral and written informed consent (GCP)

Exclusion Criteria:

  • other prior malignancies, except treated in situ-carcinoma of cervix or tumours of skin without indication to a melanoma (or 10 years tumourfree)
  • other participation in clinical trials within 30 days before randomization
  • previous chemotherapy (except adjuvant chemotherapy with an interval of >= 6 months)
  • creatinine clearance <50 ml/min
  • hepatic insufficiency (ALAT, ASAT, Bilirubin, AP >5 x upper limit)
  • peripheral neuropathy > CTC grade 1
  • uncontrolled cardiac insufficiency or angina pectoris
  • active infections
  • severe neurological or psychiatric illness
  • breast-feeding or pregnant women
  • incapacity to take part in regular visits
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00156975

Locations
Germany
Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik
Dresden, Sachsen, Germany, 011307
Universitaetsklinikum Essen, Klinik für Allgemein- und Transplantationschirurgie OPZ II
Essen, Germany, 45122
Klinik für Allgemein- und Gefäßchirurgie , J. W. Goethe Universität
Frankfurt Am Main, Germany, 60590
Sponsors and Collaborators
Arbeitsgruppe Lebermetastasen und Tumoren
Investigators
Principal Investigator: Wolf O. Bechstein, Prof. Dr. Arbeitsgruppe Lebermetastasen und Tumoren
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00156975     History of Changes
Other Study ID Numbers: ADHOC
Study First Received: September 9, 2005
Last Updated: December 24, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Arbeitsgruppe Lebermetastasen und Tumoren:
Oxaliplatin
Capecitabine
Chemotherapy
Resection
Liver metastases
Liver resection
Adjuvant

Additional relevant MeSH terms:
Colorectal Neoplasms
Liver Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Rectal Diseases
Capecitabine
Fluorouracil
Oxaliplatin
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014